Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
A major drawback in the clinical use of the oral anticoagulants that directly inhibit factor Xa in order to prevent blood clot formation is the potential for life threatening bleeding events. Here the authors describe factor Xa variants that are refractory to inhibition by these anticoagulants and c...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Nature Portfolio
2017-09-01
|
| Цуврал: | Nature Communications |
| Онлайн хандалт: | https://doi.org/10.1038/s41467-017-00647-9 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|